ERBB2 and breast cancer: Immunohistochemistry analysis on breast cancer tissue samples has revealed that STARD11 is downregulated in the basal-like BC subtype [113] but, conversely, CERT expression is overexpressed in HER2-positive BC and associated with poor prognoses [114].